FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4384131434> ?p ?o ?g. }

• W4384131434 abstract "Abstract Background Gene-modified cell therapy with regulatory T cells (Tregs) is a promising approach to prevent graft rejection and induce immunological tolerance in organ transplantation. We are developing a cell therapy comprising autologous naïve Tregs that are isolated from leukapheresate, transduced with lentiviral vector encoding a chimeric antigen receptor (CAR) recognising human leukocyte antigen class I molecule A*02 (HLA-A*02), and expanded ex vivo before cryopreservation as resultant drug product (TX200-TR101). In an ongoing first-in-human study (NCT04817774), kidney transplant recipients will receive a single infusion of TX200-TR101 2–3 months after transplantation. The phase 0 study described here evaluated the feasibility of manufacture of TX200-TR101 for the target population, i.e., end-stage renal disease (ESRD) necessitating kidney transplantation. Participants in this study did not receive an infusion of drug product. Methods Four patients with ESRD and HLA-A*02 negative typing underwent leukapheresis to collect starting material for manufacture of TX200-TR101. Manufacturing success criteria were predefined as a batch of CAR-Tregs with cell quantity in each batch ≥ 10 4 cells/kg body weight, cell viability ≥ 70%, transduction efficiency ≥ 20% and hypomethylation of the FoxP3 gene (Treg-specific demethylated region [TSDR]) ≥ 80%. Other manufacturing variables included Treg identity and maturation by phenotyping, residual bead count, vector copy number, endotoxin level, sterility, and presence of mycoplasma. The characteristics of leukapheresate starting material and drug product from patients with ESRD were compared with those from commercially purchased leukapheresate from 10 healthy donors. Results No safety issues were identified during leukapheresis collections. Batches of drug product were manufactured from all 4 patients with ESRD and met the predefined success criteria. There was some variability in leukapheresate starting material in terms of volume of apheresis and total leukocyte counts between patients with ESRD and healthy donors, but percentage differential white blood cell counts were comparable. The quality, quantity and functional activity of manufactured CAR-Tregs were similar between ESRD patients and healthy donors. CAR-Treg drug product from one patient with pre-existing lymphopenia had similar high quality but reduced cell quantity compared with batches from the other patients with ESRD, although yield was still above the predefined target minimum number of cells. Conclusions Manufacture of high-quality naïve CAR-Tregs from patients with ESRD is safe and feasible." @default.
• W4384131434 created "2023-07-14" @default.
• W4384131434 creator A5018381275 @default.
• W4384131434 creator A5026128902 @default.
• W4384131434 creator A5033988614 @default.
• W4384131434 creator A5040930081 @default.
• W4384131434 creator A5047727824 @default.
• W4384131434 creator A5048327759 @default.
• W4384131434 creator A5051127450 @default.
• W4384131434 creator A5076421702 @default.
• W4384131434 creator A5091889478 @default.
• W4384131434 date "2023-07-13" @default.
• W4384131434 modified "2023-10-14" @default.
• W4384131434 title "Feasibility of manufacture of chimeric antigen receptor-regulatory T cells from patients with end-stage renal disease" @default.
• W4384131434 cites W1993310853 @default.
• W4384131434 cites W2035788065 @default.
• W4384131434 cites W2065006357 @default.
• W4384131434 cites W2073685827 @default.
• W4384131434 cites W2103051574 @default.
• W4384131434 cites W2128737986 @default.
• W4384131434 cites W2130486201 @default.
• W4384131434 cites W2155965977 @default.
• W4384131434 cites W2269198676 @default.
• W4384131434 cites W2284630235 @default.
• W4384131434 cites W2518046346 @default.
• W4384131434 cites W2604386942 @default.
• W4384131434 cites W2607327912 @default.
• W4384131434 cites W2726575235 @default.
• W4384131434 cites W2791921463 @default.
• W4384131434 cites W2801024566 @default.
• W4384131434 cites W2804733622 @default.
• W4384131434 cites W2974877234 @default.
• W4384131434 cites W3026232934 @default.
• W4384131434 cites W3084488870 @default.
• W4384131434 cites W3094128707 @default.
• W4384131434 cites W3100659075 @default.
• W4384131434 cites W4224274171 @default.
• W4384131434 cites W4289918643 @default.
• W4384131434 doi "https://doi.org/10.1186/s41231-023-00150-y" @default.
• W4384131434 hasPublicationYear "2023" @default.
• W4384131434 type Work @default.
• W4384131434 citedByCount "0" @default.
• W4384131434 crossrefType "journal-article" @default.
• W4384131434 hasAuthorship W4384131434A5018381275 @default.
• W4384131434 hasAuthorship W4384131434A5026128902 @default.
• W4384131434 hasAuthorship W4384131434A5033988614 @default.
• W4384131434 hasAuthorship W4384131434A5040930081 @default.
• W4384131434 hasAuthorship W4384131434A5047727824 @default.
• W4384131434 hasAuthorship W4384131434A5048327759 @default.
• W4384131434 hasAuthorship W4384131434A5051127450 @default.
• W4384131434 hasAuthorship W4384131434A5076421702 @default.
• W4384131434 hasAuthorship W4384131434A5091889478 @default.
• W4384131434 hasBestOaLocation W43841314341 @default.
• W4384131434 hasConcept C10882517 @default.
• W4384131434 hasConcept C126322002 @default.
• W4384131434 hasConcept C147483822 @default.
• W4384131434 hasConcept C1491633281 @default.
• W4384131434 hasConcept C188280979 @default.
• W4384131434 hasConcept C203014093 @default.
• W4384131434 hasConcept C2776090121 @default.
• W4384131434 hasConcept C2779134260 @default.
• W4384131434 hasConcept C2779727006 @default.
• W4384131434 hasConcept C2780303639 @default.
• W4384131434 hasConcept C2908647359 @default.
• W4384131434 hasConcept C2911091166 @default.
• W4384131434 hasConcept C3019040382 @default.
• W4384131434 hasConcept C3875195 @default.
• W4384131434 hasConcept C54355233 @default.
• W4384131434 hasConcept C71924100 @default.
• W4384131434 hasConcept C86803240 @default.
• W4384131434 hasConcept C8891405 @default.
• W4384131434 hasConcept C99454951 @default.
• W4384131434 hasConceptScore W4384131434C10882517 @default.
• W4384131434 hasConceptScore W4384131434C126322002 @default.
• W4384131434 hasConceptScore W4384131434C147483822 @default.
• W4384131434 hasConceptScore W4384131434C1491633281 @default.
• W4384131434 hasConceptScore W4384131434C188280979 @default.
• W4384131434 hasConceptScore W4384131434C203014093 @default.
• W4384131434 hasConceptScore W4384131434C2776090121 @default.
• W4384131434 hasConceptScore W4384131434C2779134260 @default.
• W4384131434 hasConceptScore W4384131434C2779727006 @default.
• W4384131434 hasConceptScore W4384131434C2780303639 @default.
• W4384131434 hasConceptScore W4384131434C2908647359 @default.
• W4384131434 hasConceptScore W4384131434C2911091166 @default.
• W4384131434 hasConceptScore W4384131434C3019040382 @default.
• W4384131434 hasConceptScore W4384131434C3875195 @default.
• W4384131434 hasConceptScore W4384131434C54355233 @default.
• W4384131434 hasConceptScore W4384131434C71924100 @default.
• W4384131434 hasConceptScore W4384131434C86803240 @default.
• W4384131434 hasConceptScore W4384131434C8891405 @default.
• W4384131434 hasConceptScore W4384131434C99454951 @default.
• W4384131434 hasFunder F4320317951 @default.
• W4384131434 hasIssue "1" @default.
• W4384131434 hasLocation W43841314341 @default.
• W4384131434 hasOpenAccess W4384131434 @default.
• W4384131434 hasPrimaryLocation W43841314341 @default.
• W4384131434 hasRelatedWork W1997456581 @default.
• W4384131434 hasRelatedWork W2008949385 @default.
• W4384131434 hasRelatedWork W2019101100 @default.
• W4384131434 hasRelatedWork W2053177727 @default.

• next